Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response: 0								

						01 30	CHOIT	0(11) 0	ii uie ii	ivesiiie	III CUI	mpany Act o	1 1940							
Name and Address of Reporting Person*     Zawel Leigh					2. Issuer Name and Ticker or Trading Symbol  Cullinan Oncology, Inc. [ CGEM ]									(Chec	k all app Direc			erson(s) to Is 10% Ov Other (s	wner	
(Last) (First) (Middle) C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 520					3. Date of Earliest Transaction (Month/Day/Year) 08/23/2021									See Remarks						
(Street) CAMBR (City)		MA (Stat		2142 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year) 08/24/2021									6. Ind Line) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution (Execution (		cution Date,		3. Transaction Code (Instr. 8) 4. Securiti Disposed 5)		ies Acquired (A Of (D) (Instr. 3,		A) or , 4 and	Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following Reported		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	or P	rice	Transaction(s) (Instr. 3 and 4)				(111501. 4)	
Common Stock 08/23/2					2021			S <sup>(1)</sup>		28,118	Ι	)   5	\$29 <sup>(2)</sup>		93,524		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			Transaction Code (Instr. 8)  5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)  Amoun or Numbe of Title Shares		De Se (In	Price of trivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

- 1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$28.60 to \$29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

## Remarks:

Chief Scientific Officer, Small Molecules This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.

> /s/ Jeffrey Trigilio, Attorneyin-Fact

08/26/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.